Related Experiment Video
Updated: May 23, 2026
Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
Published on: April 30, 2019
Post-Marketing Surveillance Data of Adverse Events Following Immunization with Human Rabies Vaccine - China,
Lina Zhang1, Keli Li1, Yan Li1
1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
What Is Already Known About This Topic?:
Human rabies vaccine has been in use for many years and has played a vital role in rabies prevention and control in China.
What Is Added By This Report?:
From 2021 to 2024, the overall reported rate of adverse events following immunization (AEFI) with human rabies vaccine was 18.57 per 100,000 doses, of which 96.29% were common vaccine reactions. Rare vaccine reactions occurred at a rate of 0.49 per 100,000 doses; allergic rash was the most frequently reported rare reaction and usually was non-serious. The rate of rare and serious vaccine reactions was 0.07 per 100,000 doses.
What Are The Implications For Public Health Practice?:
Human rabies vaccine, one of the most commonly used non-program vaccines in China, its AEFI rate fell within an acceptable range. Continued AEFI surveillance is essential for evaluating the post-marketing immnization safety of this vaccine.
